ClinicalTrials.gg
Not yet recruitingNCT07266324Updated Dec 5, 2025

A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

A Phase 2 interventional study of BMB-101 and Placebo in Prader-Willi Syndrome, sponsored by Bright Minds Biosciences Pty Ltd. Not yet recruiting at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Bright Minds Biosciences Pty Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety and effects of a new drug called BMB-101 in people with Prader-Willi Syndrome (PWS). This study is designed as a multi-centre, double-blind, randomized, placebo controlled 2-part study with a blinded main phase followed up an open label extension phase.

Read the detailed description

This study is designed as a 2-part study:

Part 1 is designed as a randomized phase, lasting up to 16 weeks. There will be a 4-week screening period. Following the screening period, participants will be randomized in a 1:1 ratio to either BMB-101 or placebo. Participants will enter into a weekly ascending Maximum Tolerated Dose (MTD) titration phase of 4 weeks followed by a maintenance phase of 8 weeks. There will be 5 clinic visits and 4 telephone visits.

Part 2 is designed to follow after the completion of the maintenance phase in Part 1. Participants at the discretion of the Investigator may elect to continue into an unblinded, expandable open label phase to receive BMB-101.

Participants who do not elect to continue into the open label phase will be tapered from assigned study treatment over 4 weeks following completion of the maintenance phase.

02

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

03

In context

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

This study's planned enrollment of 16 is below the median of 30 across 100 interventional studies indexed under Prader-Willi Syndrome.

Browse Prader-Willi Syndrome studies →

Lead sponsor

Bright Minds Biosciences Pty Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be aged 18-65 years (both inclusive).
  • Genetically confirmed diagnosis of Prader Willi Syndrome via standard DNA testing or other commonly approved methods.
  • Willing and able to provide voluntary written , or have a Legally Authorized Representative who is able to provide consent.
  • Moderate to severe hyperphagia as defined by a HQ-CT score ≥ 13 at time of randomization (Visit 3).
  • If participant is receiving growth hormone, the subject must be on the same medication and stable dose for at least 90 days prior to Visit 1.
  • Female participant of must have a negative urine pregnancy test at baseline. Participants of childbearing or child-fathering potential must be willing to use medically acceptable forms of , which includes abstinence, while in this study and for 90 days after the last dose of study drug.
  • Participant and/or caregiver has the ability to be compliant with study requirements, including visit schedule, diary completion and study drug accountability.
  • If a caregiver assists in completion of questionnaires, the same caregiver is available to complete the questionnaires throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Participant has used metabolic agents known to affect appetite within 3 months of Visit 1.
  • Participant use of psychotropic medications including SSRIs/SNRIs, monoamine-oxidase inhibitors, tricyclic antidepressants, other serotonergic agonists or antagonists (antipsychotics), and other agents which have known Serotonin Syndrome risk (e.g. mirtazapine) within 1 month of Visit 1.
  • Participant has implementation of new food restrictions or new environmental restrictions within 1 month of Visit 1.
  • Participant has participated in an interventional clinical trial of any Prader-Willi Syndrome agent within 3 months of Visit 1 or any other agent within 1 month of Visit 1.
  • Participant has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, pulmonary hypertension, myocardial infarction or stroke, or structural cardiac abnormality.
  • Participant has moderate or severe hepatic impairment. Asymptomatic participants with mild hepatic impairment (elevated liver enzymes \< 3x (ULN) and/or elevated \<2x ULN) may be entered into the study after review and approval by the Medical Monitor in conjunction with the sponsor, in consideration of comorbidities and concomitant medications.
  • Participant has severe renal impairment (estimated \<30mL/min/1.73m2).
  • Participant has clinically significant abnormality such as >450 msec (males) or >470 msec (females).
  • Participant has a history of drug or alcohol abuse within the last 12 months or a positive urine drug screen.
  • A current C-SSRS score of 4 or 5 at Visit 1 or history of suicide attempt at any time during the past year.
  • Participant has a clinically significant condition or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to Visit 1, other than PWS, that would negatively impact study participation, collection of study data, evaluation of study endpoints or pose a risk to the participant, in the opinion of the Investigator.
  • Participant is pregnant (determined by a positive urine pregnancy test) or lactating female.
  • Any condition that is thought to be a degenerative neurological disease.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    BMB-101

    Participants receive BMB-101 (10mg/mL liquid) orally

    Drug: BMB-101

  • Placebo comparator
    Placebo

    Participants receiving matched placebo orally

    Drug: Placebo

Interventions

  • Participants will receive weekly ascending oral doses of BMB-101(10 mg/mL) twice daily (BID) for 16 weeks. Doses will be based on weight (kg) and will initially start at 1.67 mg/kg. Doses may be titrated in 0.33 mg/kg increments based on tolerability up to a maximum dose of 2.0 mg/kg.

  • DrugPlacebo

    Matched Placebo

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hyperphagia Questionnaire for Clinical Trials scores over time in Prader-Willi Syndrome participants.

    The Hyperphagia Questionnaire for Clinical Trials consists of 9 items; each rated on a scale from 0 (no symptoms) to 4 (severe symptoms). The total score ranges from 0 to 36, with higher scores indicating worse hyperphagia symptoms. A score of approximately 13 is associated with moderate to severe hyperphagia, and a score of 22 or greater is associated with severe hyperphagia.

    Time frame: 16 weeks

Secondary outcomes

  1. Change from Baseline in hyperphagia severity score as measured by the Caregiver Global Impression of Severity 7-point scale over time.

    This scale is a single-item measure from 1 to 7, where higher scores indicate greater severity.

    Time frame: 16 weeks

  2. Change from Baseline in hyperphagia severity score as measured by the Clinician Global Impression of Severity 7-point scale over time.

    This scale is a single-item measure from 1 to 7, where higher scores indicate greater severity.

    Time frame: 16 weeks

  3. Change from Baseline in severity of Prader-Willi Syndrome disease scores as measured by the Clinician Global Impression of Severity 7-point scale over time.

    This scale is a single-item measure from 1 to 7, where higher scores indicate greater severity.

    Time frame: 16 weeks

  4. Change from Baseline in improvement of Prader-Willi Syndrome disease scores as measured by the Clinician Global Impression of Improvement 7-point scale over time.

    This scale is a single-item measure from 1 to 7, where 1 indicates very much improved, and 7 indicates very much worse.

    Time frame: 16 weeks

  5. Change from Baseline in Prader-Willi Syndrome correlated behavioral issues such as symptoms measured by the Prader-Willi Syndrome Profile on a 3-point scale over time.

    The Prader-Willi Syndrome Profile is a 57-item caregiver rated questionnaire that measures 52 Prader-Willi Syndrome specific behaviors on a 3-point scale (0-2), where 0=Not True, and 2=Often True. Higher scores indicate greater severity.

    Time frame: 16 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Nov 2026, 10 months later.

Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 5, 2025
StartEst.
Jan 2026
Primary completionEst.
Nov 2026
CompletionEst.
Mar 2027
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07266324
Lead sponsor
Bright Minds Biosciences Pty Ltd
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Jan 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Dec 5, 2025

Study contacts

Rachelle Kirk-Burnnand
Contact
rachelle@basebio.com.au
+61 439615368

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMB-101

Start the discussion